JB Chemicals & Pharmaceuticals Limited
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage … Read more
JB Chemicals & Pharmaceuticals Limited - Asset Resilience Ratio
JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) has an Asset Resilience Ratio of 19.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how JB Chemicals & Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down JB Chemicals & Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹1.04 Billion | 2.21% |
| Short-term Investments | ₹8.08 Billion | 17.14% |
| Total Liquid Assets | ₹9.12 Billion | 19.35% |
Asset Resilience Insights
- Good Liquidity Position: JB Chemicals & Pharmaceuticals Limited maintains a healthy 19.35% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
JB Chemicals & Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio
Compare JB Chemicals & Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for JB Chemicals & Pharmaceuticals Limited (2006–2025)
The table below shows the annual Asset Resilience Ratio data for JB Chemicals & Pharmaceuticals Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 8.68% | ₹3.71 Billion | ₹42.74 Billion | -1.21pp |
| 2024-03-31 | 9.89% | ₹3.95 Billion | ₹39.94 Billion | +3.05pp |
| 2023-03-31 | 6.83% | ₹2.43 Billion | ₹35.54 Billion | +6.76pp |
| 2022-03-31 | 0.07% | ₹19.26 Million | ₹26.07 Billion | -29.79pp |
| 2021-03-31 | 29.86% | ₹6.68 Billion | ₹22.38 Billion | +9.86pp |
| 2020-03-31 | 20.01% | ₹3.63 Billion | ₹18.14 Billion | -0.98pp |
| 2019-03-31 | 20.99% | ₹3.76 Billion | ₹17.91 Billion | -1.10pp |
| 2018-03-31 | 22.09% | ₹3.90 Billion | ₹17.65 Billion | +8.65pp |
| 2017-03-31 | 13.44% | ₹2.25 Billion | ₹16.74 Billion | +0.90pp |
| 2016-03-31 | 12.54% | ₹1.95 Billion | ₹15.57 Billion | -24.84pp |
| 2015-03-31 | 37.38% | ₹5.56 Billion | ₹14.87 Billion | +0.58pp |
| 2014-03-31 | 36.81% | ₹4.97 Billion | ₹13.51 Billion | +6.20pp |
| 2013-03-31 | 30.61% | ₹3.98 Billion | ₹13.00 Billion | +5.65pp |
| 2012-03-31 | 24.96% | ₹2.99 Billion | ₹11.98 Billion | +18.14pp |
| 2011-03-31 | 6.82% | ₹681.15 Million | ₹9.99 Billion | -0.32pp |
| 2010-03-31 | 7.13% | ₹596.82 Million | ₹8.37 Billion | -0.64pp |
| 2009-03-31 | 7.77% | ₹579.99 Million | ₹7.46 Billion | -0.34pp |
| 2008-03-31 | 8.11% | ₹601.32 Million | ₹7.41 Billion | +2.87pp |
| 2007-03-31 | 5.24% | ₹373.14 Million | ₹7.12 Billion | -0.01pp |
| 2006-03-31 | 5.25% | ₹265.04 Million | ₹5.05 Billion | -- |